Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019067540) TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/067540 International Application No.: PCT/US2018/052855
Publication Date: 04.04.2019 International Filing Date: 26.09.2018
IPC:
A61F 9/007 (2006.01) ,A61K 39/395 (2006.01) ,A61M 5/32 (2006.01) ,A61P 27/02 (2006.01)
[IPC code unknown for A61F 9/07]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
M
DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
5
Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
178
Syringes
31
Details
32
Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
Applicants:
REGENXBIO INC. [US/US]; 9600 Blackwell Road, Suite 210 Rockville, MD 20850, US
THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street Baltimore, MD 21218, US
Inventors:
YOO, Stephen; US
REINHARDT, Rickey, Robert; US
VAN EVEREN, Sherri; US
KOZARSKY, Karen, Fran; US
SIMPSON, Curran, Matthew; US
WU, Zhuchun; US
CAMPOCHIARO, Peter, Anthony; US
SHEN, Jikui; US
DING, Kun; US
Agent:
MARTINEK, Sebastian; US
MCNICHOLAS, Janet; US
ANTLER, Adriane; US
CORUZZI, Laura; US
PAULSON, Mark; US
Priority Data:
62/564,09527.09.2017US
62/574,65719.10.2017US
62/579,68231.10.2017US
62/632,81220.02.2018US
Title (EN) TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB
(FR) TRAITEMENT DE MALADIES OCULAIRES AVEC UN FAB ANTI-VEGF À MODIFICATION POST-TRADUCTIONNELLE TOTALEMENT HUMAIN
Abstract:
(EN) Compositions and methods are described for the delivery of a fully human post- translationally modified (HuPTM) monoclonal antibody ("mAb") or the antigen-binding fragment of a mAb against human vascular endothelial growth factor ("hVEGF") - such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment - to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration ("nAMD"), also known as "wet" age-related macular degeneration ("WAMD"), age-related macular degeneration ("AMD"), and diabetic retinopathy.
(FR) La présente invention concerne des compositions et des procédés pour l'administration d'un anticorps monoclonal ("mAb") à modification post-traductionnelle totalement humain (HuPTM) ou le fragment de liaison à l'antigène d'un facteur de croissance endothélial vasculaire humain ("hVEGF") dirigé contre un mAb, - tel que, par exemple, un fragment de liaison d'antigène anti-hVEGF glycosylé totalement humain (HuGly) - dans la rétine/l'humeur vitrée dans l'œil/les yeux de sujets humains chez qui l'on a diagnostiqué des maladies oculaires causées par une néovascularisation accrue, par exemple, la dégénérescence maculaire liée à l'âge néovasculaire ("DMLAn"), également appelée dégénérescence maculaire liée à l'âge "humide" ("DMLAH"), la dégénérescence maculaire liée à l'âge ("DMLA") et la rétinopathie diabétique.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)